A natural history of familial platelet disorder with myeloid malignancy; HEXIM1 as an essential transcription regulator in erythropoiesis; residual disease predicts relapse in CML patients

A natural history of familial platelet disord...

Up next

New Research: Mitochondrial DNA in TRALI and Venetoclax-Obinituzumab in CLL Trials

In this week's episode, associate editor Dr. James Griffin interviews researchers Dr. John Semple and Dr. Othman Al-Sawaf on their groundbreaking studies on transfusion-related acute lung injury and chronic lymphocytic leukemia treatment. Dr. Semple explored how mitochondrial DNA ...  Show more

Bispecific Antibodies in Aggressive B-Cell Lymphoma: Real-World Insights and Future Directions

In this week's episode, Blood editor Dr. Laura Michaelis interviews author Dr. Taylor Brooks on his latest paper published in volume 146 issue 18 of Blood Journal. The conversation discusses outcomes of bispecific antibodies (epcoritamab or glofitamab) in treating aggressive B-ce ...  Show more

Recommended Episodes

Chronic Myelogenous Leukemia
Two Onc Docs

This week’s episode will be focusing on Chronic Myeloid Leukemia or CML for health care providers. We will go over all the important details on the genetics of CML, diagnosis and treatment algorithms.

 

Multiple Myeloma
Two Onc Docs

This week’s episode is part 2 of our plasma cell dyscrasias series. We will go over the important details on risk stratification, as well as initial and relapse treatment options for Multiple Myeloma, with key details on the pharmacology of myeloma drugs.


 

Episode 116: AML Series, Pt. 2 - MDS/AML Diagnosis and Risk Stratification
The Fellow on Call: The Heme/Onc Podcast

In this week’s episode, we discuss the diagnostic criteria and risk stratification for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), building on our discussion from last week. Also, if you have not done so, please do check out our hemepath series to ensure y ...

  Show more